3 completed, 3 recruiting, 1 not yet recruiting, 1 withdrawn. 3 Phase 4, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Fontan: new trials by email Literature Review of Fontan trials Research Report on Fontan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy - Fontan, Heart Failure | Phase 4 | Recruiting | The University of Hong Kong | 30 | 2026-07-01 | 2026-07-28 |
| Cholate Clearance in Fontan and Heart Failure Dual cholate clearance assay, MRI - Fontan, Right Heart Failure | Recruiting | HepQuant, LLC | 75 | 2025-08-04 | 2026-09-17 | |
| Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry SGLT2 inhibitors - Adult Congenital Heart Disease, Congenital Heart Disease | Recruiting | Leiden University Medical Center | 400 | 2023-01-01 | 2026-02-13 | |
| Canadian Adult Congenital Heart Disease Intervention Registry Participants undergoing ACHD intervention - Atrial Septal Defect, Patent Foramen Ovale | Not yet recruiting | University Health Network, Toronto | 9000 | 2020-04-01 | 2020-02-28 | |
| Nitrate Effect on Exercise Capacitance Isosorbide Dinitrate - Fontan | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 20 | 2019-12-12 | 2021-09-22 |
| TRPV2 Agonists in the Fontan Circulation Probenecid, Placebo - Fontan | Phase 4 | Completed | Children's Hospital Medical Center, Cincinnati | 8 | 2017-03-21 | 2021-07-09 |
| Effect of Carvedilol on Exercise Performance in Fontan Patients Carvedilol, Placebo - Single Ventricle, Fontan | Phase 4 | Completed | University of Texas Southwestern Medical Center | 26 | 2016-11-01 | 2021-01-22 |
| Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients inhaled nitric oxide - Congenital Heart Disease, Fontan | Phase 3 | Withdrawn | University of California, San Francisco | 2012-06-01 | 2018-05-04 |
Heart Defects, Congenital (3) · Heart Failure (3) · Tetralogy of Fallot (2) · Transposition of Great Vessels (2) · Univentricular Heart (2) · Aortic Coarctation (1) · Cardiovascular Diseases (1) · Congenitally Corrected Transposition of the Great Arteries (1) · Foramen Ovale, Patent (1) · Heart Septal Defects, Atrial (1)
Heart Diseases (6) · Cardiovascular Abnormalities (5) · Cardiovascular Diseases (5) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Heart Defects, Congenital (2) · Heart Septal Defects (1)
Carvedilol (1) · Isosorbide Dinitrate (1) · Probenecid (1) · Sodium-Glucose Transporter 2 Inhibitors (1) · dapagliflozin (1)
Children's Hospital Medical Center, Cincinnati (2) · HepQuant, LLC (1) · Leiden University Medical Center (1) · The University of Hong Kong (1) · University Health Network, Toronto (1) · University of California, San Francisco (1) · University of Texas Southwestern Medical Center (1)
United States (6) · Canada (1) · Germany (1) · Hong Kong (1) · Netherlands (1) · North Macedonia (1) · United Kingdom (1)
Anastasia D. Egorova, MD PhD (1) · Eric Horlick, MD (1) · Jeffery Meadows, MD (1) · Lusine Abrahamyan, MD, PhD (1) · Prof Yiu Fai Cheung (1)
PMID 33585998, PMID 35355435, PMID 37084132, PMID 37435053, PMID 38530688, PMID 40689152, PMID 40695536, PMID 42181636